Celgene (CELG) Holdings Boosted by US Bancorp DE

US Bancorp DE raised its stake in shares of Celgene (NASDAQ:CELG) by 7.5% during the 1st quarter, HoldingsChannel reports. The firm owned 829,414 shares of the biopharmaceutical company’s stock after acquiring an additional 57,907 shares during the quarter. US Bancorp DE’s holdings in Celgene were worth $73,992,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of CELG. Motco lifted its stake in shares of Celgene by 442.8% in the first quarter. Motco now owns 2,361 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 1,926 shares in the last quarter. Riverhead Capital Management LLC lifted its stake in shares of Celgene by 10.3% in the first quarter. Riverhead Capital Management LLC now owns 20,585 shares of the biopharmaceutical company’s stock worth $1,836,000 after buying an additional 1,922 shares in the last quarter. Signaturefd LLC lifted its stake in shares of Celgene by 41.4% in the first quarter. Signaturefd LLC now owns 7,622 shares of the biopharmaceutical company’s stock worth $680,000 after buying an additional 2,231 shares in the last quarter. Thompson Siegel & Walmsley LLC lifted its stake in shares of Celgene by 1,770.3% in the first quarter. Thompson Siegel & Walmsley LLC now owns 49,919 shares of the biopharmaceutical company’s stock worth $4,453,000 after buying an additional 47,250 shares in the last quarter. Finally, Doliver Capital Advisors LP purchased a new position in shares of Celgene in the first quarter worth about $304,000. 75.69% of the stock is currently owned by institutional investors and hedge funds.

Shares of CELG opened at $78.37 on Monday. Celgene has a 1-year low of $78.35 and a 1-year high of $147.17. The stock has a market cap of $56.80 billion, a price-to-earnings ratio of 11.46, a P/E/G ratio of 0.49 and a beta of 1.49. The company has a quick ratio of 2.36, a current ratio of 2.53 and a debt-to-equity ratio of 3.92.

Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Friday, May 4th. The biopharmaceutical company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.09. Celgene had a net margin of 20.73% and a return on equity of 72.92%. The business had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.47 billion. During the same period last year, the business earned $1.68 earnings per share. The business’s revenue for the quarter was up 19.4% on a year-over-year basis. equities research analysts predict that Celgene will post 7.63 earnings per share for the current fiscal year.

Celgene declared that its board has approved a stock buyback plan on Wednesday, February 14th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

In other news, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $94.83, for a total value of $877,177.50. Following the completion of the transaction, the director now owns 94,801 shares of the company’s stock, valued at $8,989,978.83. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Ernest Mario sold 13,370 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $94.49, for a total transaction of $1,263,331.30. The disclosure for this sale can be found here. In the last three months, insiders sold 31,870 shares of company stock valued at $2,991,601. Insiders own 0.95% of the company’s stock.

Several equities analysts have recently weighed in on CELG shares. Mizuho reissued a “buy” rating and issued a $128.00 price target on shares of Celgene in a research note on Sunday, February 4th. Zacks Investment Research raised shares of Celgene from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a research note on Tuesday, May 1st. Morgan Stanley decreased their price target on shares of Celgene from $93.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Monday, May 7th. Credit Suisse Group set a $129.00 price target on shares of Celgene and gave the stock a “buy” rating in a research note on Tuesday, April 17th. Finally, Cann reissued a “buy” rating and issued a $163.00 price target on shares of Celgene in a research note on Thursday, February 15th. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $123.98.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply